Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come
Executive Summary
Resmetirom, Madrigal’s THRβ agonist, demonstrates safety and tolerability, and succeeds on secondary efficacy endpoints in a study serving as a precursor to the firm’s pivotal Phase III trial.